Despite the extremely promising results reported in the registration studies of Mepolizumab and Benralizumab in Patients affected by EGPA, many aspects of therapy with anti-IL-5/IL-5R drugs still remain to be clarified. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.